GENENTECH, INC for GENENTECH INC
What was lobbied
12 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
H.R. 3788, the Protecting American Innovation Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver - Issues related to compulsory licensing of foriegn patents - Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
Manufacturing MAN
Biden Administration EO 14001 A Sustainable Public Health Supply Chain Biden Administration EO 14005 Ensuring the Future Is Made in All of America by All of America's Workers Biden Administration EO 14017 Americas Supply Chains - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN NEVES | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
Defense DEF
S.2782 - National Defense Authorization Act for Fiscal Year 2022 H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - Issues related to pharmaceutical supply chains and related security issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| ELISE MARIE CONNER | — |
| DAN NEVES | — |
| CATHERINE LYTTON PHILLIPS | — |
| VALERIE REYNOLDS | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
| ANDREW WESLEY WOMACK | — |
Financial Institutions/Investments/Securities FIN
Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE LYTTON PHILLIPS | — |
Taxation/Internal Revenue Code TAX
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Copyright/Patent/Trademark CPT
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
| ANDREW WESLEY WOMACK | — |
Health Issues HCR
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAN NEVES | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
| ANDREW WESLEY WOMACK | — |
Medicare/Medicaid MMM
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
| ANDREW WESLEY WOMACK | — |
Budget/Appropriations BUD
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 S.Con.Res 14- FY2022 Budget Resolution H.R. 1319 - American Rescue Plan Act, 2021 H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight - Support for increased investments to address antimicrobial resistance. - Deficit reduction, reconciliation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
| ANDREW WESLEY WOMACK | — |
Immigration IMM
H. R. 1177, The U.S. Citizenship Act H.R. 3648, The Equal Access to Green cards for Legal Employment (EAGLE) Act of 2021 - Issues relating to limits and restrictions on the immigration of high skilled workers - Issues relating to the immigration of medical researchers
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| THOMAS L. STOLL | — |
| MATTHEW L SULKALA | — |
Pharmacy PHA
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 S.4796, The Fair Care Act of 2020 H.R.5260 - Reduced Costs and Continued Cures Act - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value - Issues related to the 340B Drug Discount Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| JILL SHOTZBERGER | — |
| MATTHEW L SULKALA | — |
| RAVI UPADHYAY | — |
| ANDREW WESLEY WOMACK | — |
Medical/Disease Research/Clinical Labs MED
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| DAN NEVES | — |
| CATHERINE LYTTON PHILLIPS | — |
| VALERIE REYNOLDS | — |
| ANDREW WESLEY WOMACK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.